Crisaborole topical ointment, 2% in adults with atopic dermatitis: A phase 2a, vehicle-controlled, proof-of-concept study

Journal of Drugs in Dermatology

Volumn 14, Issue 10, 2015, Pages 1108-1112

  Murrell, Dedee F ^a   Gebauer, Kurt ^b   Spelman, Lynda ^c   Zane, Lee T ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Fremantle Dermatology   (Australia)

^c Veracity Clinical Research   (Australia)

^d PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRISABOROLE; BORON DERIVATIVE; DERMATOLOGICAL AGENT; FUSED HETEROCYCLIC RINGS;

ADULT; AGED; APPLICATION SITE ERYTHEMA; APPLICATION SITE FOLLICULITIS; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTACT DERMATITIS; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT DURATION; CLINICAL TRIAL; CUTANEOUS DRUG ADMINISTRATION; DERMATITIS, ATOPIC; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; BICYCLO COMPOUNDS, HETEROCYCLIC; BORON COMPOUNDS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84978926390     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483-1494.
2. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349.
3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132.
4. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8(5):364-372.
5. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6(1):17-26.
6. Higgs G. Is PDE4 too difficult a drug target? Curr Opin Investig Drugs. 2010;11(5):495-498.
7. Freund YR, Akama T, Alley MR, et al. Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Lett. 2012;586(19):3410-3414.
8. Akama T, Baker SJ, Zhang YK, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009;19(8):2129-2132.
9. Nazarian R, Weinberg JM. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009;10(11):1236-1242.
10. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;60(Suppl 92):44-47.